Intraductal spread of prostate cancer into the seminal vesicles

2014 ◽  
Vol 64 (7) ◽  
pp. 1039-1041 ◽  
Author(s):  
David S Cundell ◽  
Edward Rowe ◽  
Jon Oxley
Keyword(s):  
Prostate Cancer ◽  
Seminal Vesicles ◽  
Intraductal Spread

scholarly journals OC-0078: Impact of tumor invasion on seminal vesicles mobility in radiotherapy of T3b prostate cancer

2015 ◽  
Vol 115 ◽  
pp. S39-S40
Author(s):  
M. Buijs ◽  
L. Bergsma ◽  
J. De Vries ◽  
R. Kalisvaart ◽  
F. Pos ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Invasion ◽  
Seminal Vesicles

Dosimetric evaluation of whole-pelvis radiation therapy of prostate cancers: clinical experience

2020 ◽  
pp. 1-15
Author(s):  
Ernest Osei ◽  
Hafsa Mansoor ◽  
Johnson Darko ◽  
Beverley Osei ◽  
Katrina Fleming ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
High Risk ◽  
Cancer Patients ◽  
Seminal Vesicles ◽  
Conformity Index ◽  
Prostate Bed ◽  
Risk Patients ◽  
Treatment Plans ◽  
The Mean

Abstract Background: The standard treatment modalities for prostate cancer include surgery, chemotherapy, hormonal therapy and radiation therapy or any combination depending on the stage of the tumour. Radiation therapy is a common and effective treatment modality for low-intermediate-risk patients with localised prostate cancer, to treat the intact prostate and seminal vesicles or prostate bed post prostatectomy. However, for high-risk patients with lymph node involvement, treatment with radiation will usually include treatment of the whole pelvis to cover the prostate and seminal vesicles or prostate bed and the pelvic lymph nodes followed by a boost delivery dose to the prostate and seminal vesicles or prostate bed. Materials and Methods: We retrospectively analysed the treatment plans for 179 prostate cancer patients treated at the cancer centre with the volumetric-modulated arc therapy (VMAT) technique via RapidArc using 6 MV photon beam. Patients were either treated with a total prescription dose of 78 Gy in 39 fractions for patients with intact prostate or 66 Gy in 33 fractions for post prostatectomy patients. Results: There were 114 (64%) patients treated with 78 Gy/39 and 65 (36%) treated with 66 Gy/34. The mean homogeneity index (HI), conformity index (CI) and uniformity index (UI) for the PTV-primary of patients treated with 78 Gy are 0.06 ± 0.01, 1.04 ± 0.01 and 0.99 ± 0.01, respectively, and the corresponding mean values for patients treated with 66 Gy are 0.06 ± 0.02, 1.05 ± 0.01 and 0.99 ± 0.01, respectively. The mean PTV-primary V95%, V100% and V105% are 99.5 ± 0.5%, 78.8 ± 12.2% and 0.1 ± 0.5%, respectively, for patients treated with 78 Gy and 99.3 ± 0.9%, 78.1 ± 10.6% and 0.1 ± 0.4%, respectively, for patients treated with 66 Gy. The rectal V50Gy, V65Gy, V66.6Gy, V70Gy, V75Gy and V80Gy are 26.8 ± 9.1%, 14.2 ± 5.3%, 13.1 ± 5.0%, 10.8 ± 4.3%, 6.9 ± 3.1% and 0.1 ± 0.1%, respectively, for patients treated with 78 Gy and 33.7 ± 8.4%, 14.1 ± 4.5%, 6.7 ± 4.5%, 0.0 ± 0.2%, 0.0% and 0.0%, respectively, for patients treated with 66 Gy. Conclusion: The use of VMAT technique for radiation therapy of high-risk prostate cancer patients is an efficient and reliable method for achieving superior dose conformity, uniformity and homogeneity to the PTV and minimal doses to the organs at risk. Results from this study provide the basis for the development and implementation of consistent treatment criteria in radiotherapy programs, have the potential to establish an evaluation process to define a consistent, standardised and transparent treatment path for all patients that reduces significant variations in the acceptability of treatment plans and potentially improve patient standard of care.

Nucleolin and Nucleophosmin Expression in Gleason 3 and Gleason 4 Prostate Cancer With Seminal Vesicles Invasion (pT3b)

2020 ◽  
Vol 40 (4) ◽  
pp. 1973-1979 ◽  
Author(s):  
MAREK MASIUK ◽  
MAGDALENA LEWANDOWSKA ◽  
EWA DOBAK ◽  
ELZBIETA URASINSKA
Keyword(s):  
Prostate Cancer ◽  
Seminal Vesicles

Echo-Guided Biopsy and Mapping in the Diagnosis and Local Staging of Prostate Cancer

1997 ◽  
Vol 64 (3) ◽  
pp. 291-295
Author(s):  
G. Ferrari ◽  
G. Castagnetti ◽  
A. Dotti ◽  
A.M. Cesinaro ◽  
C. De Gaetani ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gleason Score ◽  
Clinical Evaluation ◽  
Malignant Disease ◽  
Seminal Vesicles ◽  
Clinical Staging ◽  
Prostate Biopsies ◽  
Guided Biopsy ◽  
Local Staging ◽  
Prostate Capsule

The incidence of prostate cancer is rising and great attention has to be paid when staging this malignant disease in order to avoid unnecessary surgery. Techniques for diagnosis by biopsy are by now standardised, but clinical staging has a high percentage of understaging (over 43%). Multiple sextant prostate biopsies involving the seminal vesicles and prostate capsule seem to be basic for current staging. These data associated with PSA, volume of the cancer and the Gleason score are the most objective and reliable parameters for correct clinical evaluation of prostate cancer.

scholarly journals Helical Tomotherapy with Simultaneous Integrated Boost for High-Risk and Lymph Node-Positive Prostate Cancer: Early Report on Acute and Late Toxicity

2009 ◽  
Vol 8 (5) ◽  
pp. 353-359 ◽  
Author(s):  
Benedikt Engels ◽  
Guy Soete ◽  
Koen Tournel ◽  
Samuel Bral ◽  
Peter De Coninck ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Side Effects ◽  
High Risk ◽  
Dose Escalation ◽  
Helical Tomotherapy ◽  
Seminal Vesicles ◽  
Node Positive ◽  
Integrated Boost ◽  
Lymph Node Positive

The use of whole pelvic radiotherapy (WPRT) for high-risk and lymph node-positive prostate cancer (PC) remains controversial. The purpose of this study was to evaluate the acute toxicity associated with helical tomotherapy in the treatment of high-risk and lymph node-positive prostate cancer. To do so, twenty-eight patients were treated to a dose of 54 Gy in daily fractions of 1.8 Gy to the pelvic lymph node area, while the prostate and the seminal vesicles received a simultaneous integrated boost (SIB) to a dose of 70.5 Gy. A SIB to a dose of 60 Gy was delivered to the involved lymph node region(s) in 8 patients with pelvic lymph node metastases. All patients received concurrent hormonal treatment. The incidence of grade 2 and 3 acute gastrointestinal (GI) toxicity was 7% and 0% respectively. Grade 2 and 3 acute genito-urinary (GU) side effects were observed in 14% and 4% of the patients respectively. No grade 4 side effects occurred. No increased toxicity was observed in the 8 lymph node-positive patients receiving a simultaneous pelvic nodal dose escalation. In conclusion, WPRT with a SIB to the prostate and seminal vesicles by helical tomotherapy resulted in a favourable toxicity profile. Pelvic nodal dose escalation in node-positive patients is feasible without increasing toxicity.

Sign in / Sign up

Export Citation Format

Share Document